Liptruzet FDA Approval History
FDA Approved: Yes (Discontinued) (First approved May 3, 2013)
Brand name: Liptruzet
Generic name: atorvastatin and ezetimibe
Dosage form: Tablets
Company: Merck
Treatment for: High Cholesterol, Familial Heterozygous
Marketing Status: Discontinued
Liptruzet (atorvastatin and ezetimibe) is a statin (HMG-CoA reductase inhibitor) and cholesterol absorption inhibitor combination indicated for the treatment of hyperlipidemia.
Development timeline for Liptruzet
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.